New peptides B7-33 develop base on Relaxin-2 Antifibrotic treatment - RM7.00
Date Posted: 06-05-2024 09:51 AM
Location: hk, Johor
Posted by: alisa
Views: 85 times
What are B7-33 peptides?
https://www.astersteroids.com/new-peptides-b7-33-develop-base-on-relaxin-2-antifibrotic-treatment-of-acute-heart-failure-and-myocardial-infarction/
B7-33 is a functional selective Relaxin-receptor 1 agonist in development, derived from the naturally occurring human hormone Relaxin-2.
Relaxin's peptides are structurally similar to insulin-like peptides in that they consist of two chains of 53 amino acids, chain A and chain B, which are connected by three disulfide bonds to function. This chemical structure makes it difficult to recombine or chemically synthesize, so the researchers determined its minimum active structure on the basis of Relaxin and developed a single B-chain peptide analogue B7-33.
The name B7-33 derives from the fact that it contains these 27 residues between 7-33 in the B-chain amino acids in Relaxin, hence the name B7-33.
Use of B7-33 peptides
B7-33 is the smallest active structure in Relaxin-2 and has similar effects to Relaxin, such as vascular dilation, increased renal blood flow, increased pumping volume in patients with acute heart failure without increasing cardiac burden, rapid anti-inflammatory, anti-hypertrophy, anti-fibrosis, etc. In the treatment of myocardial infarction, B7-33 induces a link between mitogen-activated protein kinase signaling and the heart's unfolded protein response after infarction, which has a protective effect against ischemia-reperfusion injury after myocardial infarction and promotes pro-inflammatory changes in the tissue during the early stages of infarct healing. B7-33 is also expected to be used in the production of anti-fibrotic materials or materials that resist foreign body reactions.
https://www.astersteroids.com/new-peptides-b7-33-develop-base-on-relaxin-2-antifibrotic-treatment-of-acute-heart-failure-and-myocardial-infarction/
B7-33 is a functional selective Relaxin-receptor 1 agonist in development, derived from the naturally occurring human hormone Relaxin-2.
Relaxin's peptides are structurally similar to insulin-like peptides in that they consist of two chains of 53 amino acids, chain A and chain B, which are connected by three disulfide bonds to function. This chemical structure makes it difficult to recombine or chemically synthesize, so the researchers determined its minimum active structure on the basis of Relaxin and developed a single B-chain peptide analogue B7-33.
The name B7-33 derives from the fact that it contains these 27 residues between 7-33 in the B-chain amino acids in Relaxin, hence the name B7-33.
Use of B7-33 peptides
B7-33 is the smallest active structure in Relaxin-2 and has similar effects to Relaxin, such as vascular dilation, increased renal blood flow, increased pumping volume in patients with acute heart failure without increasing cardiac burden, rapid anti-inflammatory, anti-hypertrophy, anti-fibrosis, etc. In the treatment of myocardial infarction, B7-33 induces a link between mitogen-activated protein kinase signaling and the heart's unfolded protein response after infarction, which has a protective effect against ischemia-reperfusion injury after myocardial infarction and promotes pro-inflammatory changes in the tissue during the early stages of infarct healing. B7-33 is also expected to be used in the production of anti-fibrotic materials or materials that resist foreign body reactions.
